Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alicia Okines

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
Clinical and Experimental Dermatology|April 17, 2025
Grade 3 and Grade 4 Cutaneous toxicities in patients across multiple solid tumour types receiving checkpoint inhibitor therapy: An observational study. The experience of a single large specialist institutionZaina Sharif, James Larkin, Lisa Pickering, et al.
Cancers|August 29, 2024
The Clinical Features and Outcomes of Pseudocirrhosis in Breast CancerEdward Phillips, Mantegh Sethi, Surammiya Vasanthakumar, et al.
Breast Cancer Research and Treatment|February 4, 2022
Clinical outcomes in patients with triple negative or HER2 positive lobular breast cancer: a single institution experienceAlicia Okines, Tazia Irfan, Bernice Asare, et al.
The Breast Journal|August 24, 2017
Development and responses of brain metastases during treatment with trastuzumab emtansine (T-DM1) for HER2 positive advanced breast cancer: A single institution experienceAlicia Okines, Tazia Irfan, Komel Khabra, et al.
Cancer Treatment and Research Communications|July 4, 2020
Safety and efficacy of T-DM1 in patients with advanced HER2-positive breast cancer The Royal Marsden experienceNicolò Matteo Luca Battisti, Frances Rogerson, Karla Lee, et al.
Cancer Treatment Reviews|November 24, 2024
Expert recommendations on treatment sequencing and challenging clinical scenarios in human epidermal growth factor receptor 2-positive (HER2-positive) metastatic breast cancerRupert Bartsch, David Cameron, Eva Ciruelos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2017
Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) ChemotherapyElizabeth Smyth, Shenli Zhang, David Cunningham, et al.
Breast (Edinburgh, Scotland)|October 3, 2017
Treatment and prognosis of leptomeningeal disease secondary to metastatic breast cancer: A single-centre experienceBelinda Kingston, Hamzeh Kayhanian, Chloe Brooks, et al.
European Heart Journal. Acute Cardiovascular Care|August 28, 2021
Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology-Part 1: acute coronary syndromes and acute pericardial diseasesSofie A Gevaert, Sigrun Halvorsen, Peter R Sinnaeve, et al.
JAMA Oncology|February 28, 2017
Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) TrialElizabeth C Smyth, Andrew Wotherspoon, Clare Peckitt, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
Clinical and Experimental Dermatology|April 17, 2025
Grade 3 and Grade 4 Cutaneous toxicities in patients across multiple solid tumour types receiving checkpoint inhibitor therapy: An observational study. The experience of a single large specialist institutionZaina Sharif, James Larkin, Lisa Pickering, et al.
Cancers|August 29, 2024
The Clinical Features and Outcomes of Pseudocirrhosis in Breast CancerEdward Phillips, Mantegh Sethi, Surammiya Vasanthakumar, et al.
Breast Cancer Research and Treatment|February 4, 2022
Clinical outcomes in patients with triple negative or HER2 positive lobular breast cancer: a single institution experienceAlicia Okines, Tazia Irfan, Bernice Asare, et al.
The Breast Journal|August 24, 2017
Development and responses of brain metastases during treatment with trastuzumab emtansine (T-DM1) for HER2 positive advanced breast cancer: A single institution experienceAlicia Okines, Tazia Irfan, Komel Khabra, et al.
Cancer Treatment and Research Communications|July 4, 2020
Safety and efficacy of T-DM1 in patients with advanced HER2-positive breast cancer The Royal Marsden experienceNicolò Matteo Luca Battisti, Frances Rogerson, Karla Lee, et al.
Cancer Treatment Reviews|November 24, 2024
Expert recommendations on treatment sequencing and challenging clinical scenarios in human epidermal growth factor receptor 2-positive (HER2-positive) metastatic breast cancerRupert Bartsch, David Cameron, Eva Ciruelos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2017
Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) ChemotherapyElizabeth Smyth, Shenli Zhang, David Cunningham, et al.
Breast (Edinburgh, Scotland)|October 3, 2017
Treatment and prognosis of leptomeningeal disease secondary to metastatic breast cancer: A single-centre experienceBelinda Kingston, Hamzeh Kayhanian, Chloe Brooks, et al.
European Heart Journal. Acute Cardiovascular Care|August 28, 2021
Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology-Part 1: acute coronary syndromes and acute pericardial diseasesSofie A Gevaert, Sigrun Halvorsen, Peter R Sinnaeve, et al.
JAMA Oncology|February 28, 2017
Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) TrialElizabeth C Smyth, Andrew Wotherspoon, Clare Peckitt, et al.
Pageof 4